Engineering Your Medical Device Innovations™

♦ 7755 South Research Drive ♦ Suite 110 ♦ Tempe, Arizona USA 85284 ♦ PHONE 480-813-4884 ♦ FAX 480-813-4807

CONTACT: Dr. Mark C. Johnson FOR IMMEDIATE RELEASE
Telephone: 480-813-4884
Cell: 480-797-0712
E-mail: mark.johnson@padtinc.com

ARIZONA COMPANY TO DEVELOP BIOPSY DEVICE DESIGNED TO ACCELERATE CANCER RESEARCH
Device Will Help Researchers Preserve Molecular Profile in Tumor Biopsies

TEMPE, Ariz., Oct. 20, 2009 – Phoenix Analysis & Design Technologies (PADT), an Arizona company, has received a Cancer Institute grant to develop a system to preserve tumor biopsies. The US spends approximately $60bn/yr to treat cancer and researchers are working hard to develop more effective treatments. However, clinicians often have only crude methods – such as monitoring tumor size – to evaluate various therapies. PADT’s new device will help researchers preserve the molecular profile in biopsies and thus provide a snapshot of the tumor biology which enables researchers to more directly evaluate drug efficacy.
“Each tumor is unique and understanding the specific molecular components within an individual tumor – and how those components interact at different phases of growth – is critical to guiding drug development and selecting the appropriate therapy,” according to Dr. Amanda Baker from the Arizona Cancer Center (AZCC). Unfortunately, biopsied material can decay within minutes after removal from the body – thus destroying the precise biological data that researchers need.
PADT’s device will mitigate this decay problem and allow researchers to collect and “fixate”, or preserve, the sample immediately and automatically. “The device provides consistency”, stated engineering manager Scott Klopfenstein. “Our challenge is to develop a system that integrates well with existing biopsy procedures and provides researchers with an easy way to consistently and automatically preserve the molecular profile in sampled tumors.” By collecting these snapshots as a tumor progresses and correlating the measured profiles with various drug therapies, adjustments to drug formulations and therapies can be made to greatly enhance our ability to combat cancer.
PADT is funding this effort initially with a $250,000 grant provided by the National Cancer Institute (NCI) and roughly $50,000 of its own IR&D funding. PADT will lead the effort but will work closely with collaborators at the Arizona Cancer Center (AZCC, http://www.azcc.arizona.edu/) and the Translational Genomics Research Institute (TGEN, http://www.tgen.org/). PADT has been in business since 1994 and helps commercialize new medical devices and biotechnologies (www.padtmedical.com).
###
If you would like more information about this topic, or to schedule an interview, please call Mark Johnson at 480-813-4884 or e-mail at: markj@padtmedical.com